• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Convalescent plasma is ineffective for covid-19.

作者信息

Pathak Elizabeth B

机构信息

Women's Institute for Independent Social Enquiry, Olney, MD, USA.

出版信息

BMJ. 2020 Oct 22;371:m4072. doi: 10.1136/bmj.m4072.

DOI:10.1136/bmj.m4072
PMID:33093025
Abstract
摘要

相似文献

1
Convalescent plasma is ineffective for covid-19.康复期血浆对新冠病毒肺炎无效。
BMJ. 2020 Oct 22;371:m4072. doi: 10.1136/bmj.m4072.
2
Why should we use convalescent plasma for COVID-19?我们为什么要将康复期血浆用于治疗新冠肺炎？
Eur J Intern Med. 2020 Jul;77:150-151. doi: 10.1016/j.ejim.2020.05.019. Epub 2020 May 16.
3
Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19.用一种旧疗法对抗一种新疾病：用于治疗新冠肺炎的康复期血浆
JAMA. 2020 Jun 2;323(21):2114-2117. doi: 10.1001/jama.2020.7456.
4
Convalescent plasma for covid-19.用于治疗新冠病毒肺炎的康复期血浆
BMJ. 2020 Sep 15;370:m3516. doi: 10.1136/bmj.m3516.
5
[Use of convalescent plasma for COVID-19 treatment. History and evidence].[康复期血浆用于新型冠状病毒肺炎治疗。历史与证据]
Medicina (B Aires). 2020;80 Suppl 3:82-86.
6
Convalescent Plasma and COVID-19.康复期血浆与2019冠状病毒病
JAMA. 2020 Aug 4;324(5):524. doi: 10.1001/jama.2020.10699.
7
Challenges of Convalescent Plasma Therapy on COVID-19.恢复期血浆疗法治疗新冠病毒肺炎面临的挑战
J Clin Virol. 2020 Jun;127:104358. doi: 10.1016/j.jcv.2020.104358. Epub 2020 Apr 10.
8
Isopathic Remedy Prepared from Convalescent Plasma as a Therapeutic Option for COVID-19?从康复期血浆制备的同种疗法药物能否作为治疗 COVID-19 的一种选择？
Homeopathy. 2020 Aug;109(3):184-185. doi: 10.1055/s-0040-1714061. Epub 2020 Jul 9.
9
Convalescent plasma to treat COVID-19.恢复期血浆治疗 COVID-19。
Blood. 2020 Aug 6;136(6):654-655. doi: 10.1182/blood.2020007714.
10
The resurgence of convalescent plasma therapy.恢复期血浆疗法的复兴。
Lancet Haematol. 2020 May;7(5):e353. doi: 10.1016/S2352-3026(20)30117-4.

引用本文的文献

1
Convalescent plasma therapy for coronavirus disease 2019 in ambulatory versus hospitalized patients: Efficacy and risk of thromboembolism.2019冠状病毒病门诊患者与住院患者恢复期血浆治疗：疗效及血栓栓塞风险
Res Pract Thromb Haemost. 2023 Feb;7(2):100068. doi: 10.1016/j.rpth.2023.100068. Epub 2023 Feb 6.
2
Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial.恢复期或标准血浆与常规护理治疗呼吸功能障碍的 COVID-19 患者：短期和长期效果。一项三臂随机对照临床试验。
BMC Infect Dis. 2022 Nov 22;22(1):879. doi: 10.1186/s12879-022-07716-5.
3
Early COVID-19 respiratory risk stratification using machine learning.
使用机器学习进行早期新冠病毒病的呼吸风险分层
Trauma Surg Acute Care Open. 2022 Aug 30;7(1):e000892. doi: 10.1136/tsaco-2022-000892. eCollection 2022.
4
COVID-19 convalescent plasma: current status, lessons from the past and future perspectives.COVID-19 恢复期血浆：当前状况、既往经验教训和未来展望。
Transfus Apher Sci. 2022 Aug;61(4):103487. doi: 10.1016/j.transci.2022.103487. Epub 2022 Jun 11.
5
Anti-SARS-CoV-2 IgG responses are powerful predicting signatures for the outcome of COVID-19 patients.抗 SARS-CoV-2 IgG 反应是 COVID-19 患者结局的有力预测标志物。
J Adv Res. 2021 Nov 26;36:133-145. doi: 10.1016/j.jare.2021.11.014. eCollection 2022 Feb.
6
Management of COVID patients with convalescent plasma: Do we have the final word?COVID 恢复期血浆治疗患者的管理：我们是否有定论？
Eur J Intern Med. 2022 Jan;95:13-16. doi: 10.1016/j.ejim.2021.10.029. Epub 2021 Nov 30.
7
Severe acute respiratory syndrome coronavirus 2 causes lung inflammation and injury.严重急性呼吸综合征冠状病毒 2 引起肺部炎症和损伤。
Clin Microbiol Infect. 2022 Apr;28(4):513-520. doi: 10.1016/j.cmi.2021.11.022. Epub 2021 Dec 1.
8
Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial.高滴度恢复期血浆对 COVID-19 肺炎住院患者进展为严重呼吸衰竭或死亡的影响：一项随机临床试验。
JAMA Netw Open. 2021 Nov 1;4(11):e2136246. doi: 10.1001/jamanetworkopen.2021.36246.
9
Targeting Macrophage Dysregulation for Viral Infections: Novel Targets for Immunomodulators.靶向巨噬细胞失调治疗病毒感染：免疫调节剂的新靶点。
Front Immunol. 2021 Nov 1;12:768695. doi: 10.3389/fimmu.2021.768695. eCollection 2021.
10
SARS-CoV-2 inhibition using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray.使用一种具有黏膜黏附性和两亲性的壳聚糖抑制 SARS-CoV-2，这种壳聚糖可用作抗病毒鼻腔喷雾剂。
Sci Rep. 2021 Oct 8;11(1):20012. doi: 10.1038/s41598-021-99404-8.